Skip to main content

Company

Prescient Therapeutics Ltd

ASX:PTX

Prescient Therapeutics Ltd is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies.  The company’s technologies emanate from prestigious world class centres including Yale, Penn, Oxford and Moffitt.

88 stories · page 3 of 5

Pharma & Biotech

Prescient Therapeutics CEO Yatomi-Clarke steps down; will remain available as a consultant

By Proactive 12/09/2024

Pharma & Biotech

Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research

By Proactive 05/09/2024

Pharma & Biotech

Prescient Therapeutics refines Phase 2 PTX-100 trial design for greater success

By Proactive 31/07/2024

Pharma & Biotech

Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director

By Proactive 04/07/2024

Pharma & Biotech

Prescient Therapeutics to present PTX-100 results at T-Cell Lymphoma Forum in California

By Proactive 20/05/2024

Pharma & Biotech

Prescient Therapeutics to present PTX-100 results at 5th World Congress of Cutaneous Lymphomas

By Proactive 08/04/2024

Pharma & Biotech

Prescient Therapeutics on cusp of value creation, says Pitt Street Research

By Proactive 07/03/2024

Pharma & Biotech

Prescient Therapeutics secures speculative buy recommendation from Bioshares

By Proactive 09/01/2024

Pharma & Biotech

Prescient Therapeutics’ PTX-100 Phase 1b study shows excellent safety and promising efficacy in T-cell lymphoma patients

By Proactive 11/12/2023

Pharma & Biotech

Prescient Therapeutics boosts finances with $2.4 million R&D rebate

By Proactive 28/11/2023

Pharma & Biotech

Prescient Therapeutics nearing a potential payday with PTX-100: Pitt Street Research

By Proactive 16/11/2023

Pharma & Biotech

Prescient Therapeutics to participate in prestigious conference; abstract online now

By Proactive 06/11/2023

Pharma & Biotech

Prescient Therapeutics to present clinical data at prestigious US conference

By Proactive 17/10/2023

Pharma & Biotech

Prescient Therapeutics seeks to provide new tools for clinicians in combating cancer

By Proactive 05/07/2023

Pharma & Biotech

Prescient Therapeutics to present CellPryme and OmniCAR data to International Society of Cell and Gene Therapy

By Proactive 16/05/2023

Pharma & Biotech

Prescient Therapeutics bolsters board with appointment of experienced US-based pharma executive

By Proactive 15/05/2023

Pharma & Biotech

Prescient Therapeutics' PTX-100 T Cell Lymphoma Phase 1b trial continues to show promising results

By Proactive 16/03/2023

General mining & base metals

ASX takes a dip; US$8 billion market potential in solid state batteries; average monthly mortgage up by $1,000 since April last year

By Proactive 10/03/2023

Pharma & Biotech

Prescient Therapeutics granted US FDA additional Orphan Drug Designation for PTX-100; shares up

By Proactive 09/03/2023

Pharma & Biotech

Prescient Therapeutics provides PTX-100 trial update, readies for investor briefing

Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a partial response, meaning the size of the cancer tumour has decreased.

By Proactive 02/11/2022